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LETTERS TO THE EDITORRegarding “Statin use and lower extremity amputation
risk in nonelderly diabetic patients”
Spin in scientiﬁc writing has been deﬁned as speciﬁc reporting
that could distort the interpretation of results and mislead readers.1
We believe that the results of the study by Sohn and colleagues,2
who evaluated the association between statin use and lower ex-
tremity amputation (LEA) risk in nonelderly diabetic patients,
represent an example of such a spin.
Among 83,593 cholesterol drug-naïve individuals in the study
retrospective cohort,2 217 (0.3%) experienced a major LEA dur-
ing a mean follow-up of 4.6 years (median, 5 years). Compared
with those not receiving any cholesterol-lowering medications,
users of statins were about 35% less likely to experience any
LEA (barely signiﬁcant with P ¼ .045). In particular, among pa-
tients experiencing an LEA, 32% were treated with statins, whereas
55.5% were treated with statins among those who did not experi-
ence an amputation. These ﬁndings clearly suggest that the
“reduction” of LEA by statin therapy represents only a delay in
their clinical manifestation. But, this delay is likely very small.
TheCholesterol and Recurrent Events (CARE)3 trial was a sec-
ondary prevention studywith amedian duration of follow-up similar
to that of the retrospective study by Sohn and colleagues (5 years). In
the CARE trial, patients at high risk (as deﬁned as those with 5-year
risk of major vascular events higher than 25%), randomized to pra-
vastatin 40 mg showed also a similar relative reduction of the need
for revascularization respect to the reduction of LEA in patients
studied by Sohn and colleagues. It has been calculated that the
average delay of revascularization in the CARE trial was 0.09 years
(33 days) over 5 years.4 Although it is difﬁcult to make a similar
calculation for patients analyzed by Sohn and colleagues, it seems
likely that thedelaywouldbe also lower than that observed inCARE.
Furthermore, among patients studied by Sohn and col-
leagues, 11,716 (14.0%) experienced a treatment failure, deﬁned
as an LEA or death. Users of statins were 43% less likely to expe-
rience a treatment failure compared with those not receiving any
cholesterol-lowering drugs.2 Unfortunately, the authors did not
appear to correct these results with on-study cholesterol levels,
as hypercholesterolemia is strikingly related to statin use.
In surgical patients, hypocholesterolemia represents a strong
predictor of in-hospital death, nosocomial infections, and length
of hospital stay. In particular, among patients undergoing general
surgery, a low total cholesterol level has been shown to be strongly
associatedwith death after 2 years after discharge from the hospital.5
Notably, there are not similar beneﬁcial results in randomized tri-
als, performedso far.Forexample, a subgroupanalysis of theHeartPro-
tection Study focusing on patients with peripheral artery disease and
other high-risk conditions6 avoided to consider mortality data by
combining deaths with aneurysm repairs. They found a small increase
among those randomized to simvastatin for this combined end point.6
Therefore, application of the Sohn and colleagues’ results in
clinical practice may be very difﬁcult.
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Reply
Drs Mascitelli and Goldstein take our group to task for “spin-
ning” our article to change clinical practice. Wemade no such asser-
tion or inference. Indeed, we clearly stated our study’s limitations in
the article. We noted “retrospective studies cannot exclude all sour-
ces of confounding, especially ones due to patient selection.” We
stated this explicitly because we believe retrospective data is for hy-
pothesis generating, not hypothesis proving. We think most of their
concerns (and ours) regarding statins and amputations would be
addressed by an adequately powered prospective RCT in a deﬁned
population with diabetes. That is why we proposed further research
and speciﬁcally did not urge a change in practice.
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Regarding “Management strategy for spontaneous
isolated dissection of the superior mesenteric artery
based on morphologic classiﬁcation”
We read with great interest the recent article by Li et al1 on
behalf of the Vascular Study Group of the School of Medicine, Zhe-
jiangUniversity. They raised an important issue on themanagement
of spontaneous isolated dissection of the superior mesenteric artery
(SIDSMA) based on morphologic classiﬁcation. Although the au-
thors reported a new morphologic classiﬁcation that was superior
to other classiﬁcation systems, it is less certain that the addition of
coil embolization to stent placement is better than stent placement
alone. The authors proposed early endovascular intervention, such
